Samsung Biologics showcases CMC capabilities tailored for bispecific antibody development
Predicted impact: Low
Samsung Biologics삼성바이오로직스
207940 · KOSPI · ₩SBL · 삼성바이오로직스
₩1,372,000▼ ₩2,000 (0.15%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −24.34%
- Market cap
- ₩64T
- Enterprise value
- ₩62T
- P/E
- 32.0×
- P/B
- 7.6×
- Dividend yield
- 0.0%
- ROE
- 23.7%
- Net margin
- 43.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−31.0% from the high
₩1,150,000Today: ₩1,360,000 – ₩1,399,000₩1,987,000
Returns
- 1W−3.2%
- 1M−2.0%
- 3M−7.2%
- 6M−6.9%
- YTD−19.1%
- 1Y−24.3%
- Volume today
- 50,178
- 0.6× the 20-day average
- Traded today
- ₩69B
- Listed shares
- 46,290,951
- EPS (12 months)
- ₩42,866
- Earnings yield 3.1%
AI research · Update noteModel Fair Value Estimate for Samsung Biologics Rises 22.9% to ₩580,299 Base CaseThe higher model range reflects a modest change in inputs, not new evidence from a filing in the data.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- SentimentNegativeNews: Labour talks could fail and lead to strikes. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0.4% over the last month; the price is above its 20-day average.
- News impactSome63 news items and filings in two weeks; 0 rated high impact, 21 medium.
- StreetSteady4 brokers, average target 43% from the price; last 30 days: 0 raised, 0 cut.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 28: buy ₩20B at the close (18.3% of 20-day average trading value)
On its 14 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 10.2% of trading value and pointed the same way 9 of 14 times.
- 2× KODEX Leverage ₩10B
- -2× KODEX 200 Futures Inverse 2X ₩6.1B
- -1× KODEX Inverse ₩1.1B
- 2× TIGER 200IT Leverage ₩751M
- 2× TIGER Leverage ₩424M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- KODEX 2001.4%
- TIGER 2001.4%
- KODEX 200TR1.4%
- KODEX Leverage2×1.4%
- RISE 2001.4%
- ACE 2001.4%
- KIWOOM 200TR1.4%
- PLUS 2001.4%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 1,380,000
Basis +0.58% · implied rate +14.1%
Open interest 7,386 contracts
Options open interest: 1,978 calls, 2,637 puts (put/call 1.33)
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Samsung Biologics stock overview
Samsung Biologics (삼성바이오로직스, KRX: 207940) is listed on KOSPI, in the Biotech & Pharma sector. Samsung Biologics is a Korean contract development and manufacturing organization (CDMO) that provides biopharmaceutical contract manufacturing and cell line and process development services to pharmaceutical customers. Its shares closed at ₩1,372,000 on Oct 28, 2026, down 0.15% on the day, giving it a market value of ₩64T.
Key facts
- Market cap
- ₩64T
- Sector
- Biotech & Pharma
- Latest price change
- −0.15%
- As of
- Oct 28, 2026
- Main business
- Samsung Biologics is a Korean contract development and manufacturing organization (CDMO) that provides biopharmaceutical contract manufacturing and cell line and process development services to pharmaceutical customers.
Quick answers about Samsung Biologics
- What does Samsung Biologics do?
- Samsung Biologics is a Korean contract development and manufacturing organization (CDMO) that provides biopharmaceutical contract manufacturing and cell line and process development services to pharmaceutical customers. Its products are mainly antibody drug products, and its revenue comes largely from Europe and the United States, with production based in Incheon Songdo. The company is expanding into mRNA, ADC, and cell and gene therapy manufacturing, and has launched a Samsung Organoid research service.
- What is the market cap of Samsung Biologics?
- The market capitalisation of Samsung Biologics was ₩64T at the close on Oct 28, 2026.
- What is the analyst target price for Samsung Biologics?
- The average target price of 4 brokers covering Samsung Biologics is ₩1,962,500 (range ₩1,900,000 to ₩2,000,000), 43.0% above versus the latest price, based on each broker's latest public report within six months.
- Who are the largest shareholders of Samsung Biologics?
- According to the latest official filings, the largest reported holders are Samsung C&T (44.01%, as of Oct 23, 2026); Samsung Electronics (32.05%, as of Oct 23, 2026); National Pension Service (6.88%, as of Jul 31, 2026).
- When is the next earnings report from Samsung Biologics?
- Korean companies rarely announce results dates in advance. Based on when Samsung Biologics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Samsung Biologics?
- Yes. The National Pension Service held 6.88% of Samsung Biologics shares as of Jul 31, 2026.
Company profile
Samsung Biologics is a Korean contract development and manufacturing organization (CDMO) that provides biopharmaceutical contract manufacturing and cell line and process development services to pharmaceutical customers. Its products are mainly antibody drug products, and its revenue comes largely from Europe and the United States, with production based in Incheon Songdo. The company is expanding into mRNA, ADC, and cell and gene therapy manufacturing, and has launched a Samsung Organoid research service.
Written by AI from the company's latest annual report.
- Korean name
- 삼성바이오로직스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)BiosimilarsContract drug manufacturing (CDMO)ADC & cancer drugsPharmaceuticalsWeak won, strong exporters
- Business group
- Samsung
- CEO
- 임존종보 (Rim John Chongbo)
- Founded
- Apr 2011
- Listed
- Nov 2016
- Listed shares
- 46,290,951
- Fiscal year ends
- Month 12
- Website
- www.samsungbiologics.com
Similar companies
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
- SK Bioscience302440 · ₩2.5T₩32,150+1.26%
Recent news
삼성바이오로직스, 마지막 노사교섭…결렬 시 순차파업 돌입
Predicted impact: Medium
Final labor talks with possible sequential strikes at a major biotech; strike risk could affect output.
Samsung Biologics Enters Final Labor Talks
Predicted impact: Medium
Final labor talks with strike threat could disrupt production at a large biotech company.
Recent filings
See all- Insider shareholding reportOct 28, 2026
- Insider shareholding reportOct 26, 2026
- Insider shareholding reportOct 26, 2026
- Insider shareholding reportOct 26, 2026
- Insider shareholding reportOct 26, 2026
Titles in Korean until English translations are added.
Also known as: Samsung Biologics / 삼성바이오로직스 / 207940 / KRX:207940
Source: KRX statistical information